were done using the two imidazoles derivatives; Itraconazole (Sporanox) and Ketoconazole
(Nizoral) for treatment of cutaneous leishmaniasis in Kuwait. According to the results of
our studies, together with the results of similar studies in the literature, we are now
treating cases of cutaneous leishmaniasis in Kuwait according to the following protocol:
|1- Few small lesions are treated with
|2- Few large lesions or multiple
lesions are treated with either:
Itraconazole oral dose of 200 mg per day for a period of 6-8 weeks.
Ketoconazole oral dose of 600 mg daily for a period of 6 weeks.
|3- Resistant lesions not responding to
the above treatments are given parentral sodium stibogluconate (Pentostam).
Full-text articles demonstrating our
experience in Kuwait with these two drugs:
page on-line: French, German, Italian, Portuguese, Spanish